Morgan Stanley analyst Kallum Titchmarsh downgraded Axonics (AXNX) to Equal Weight from Overweight with a price target of $71, up from $69, following the recent announcement of its agreement to be acquired by Boston Scientific (BSX). The firm believes the deal will close as planned with a low risk of FTC pushback, as it sees no clear competitive crossover and does not expect higher bidders.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AXNX:
- Axonics downgraded to Hold from Buy at Truist
- Axonics downgraded to Neutral from Buy at CL King
- Axonics downgraded to Neutral from Overweight at Piper Sandler
- Axonics downgraded to Market Perform from Outperform at Leerink
- Axonics downgraded to Equal Weight from Overweight at Wells Fargo
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue